Wall Street brokerages expect that Steris PLC (NYSE:STE) will report earnings per share (EPS) of $1.43 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Steris’ earnings. The lowest EPS estimate is $1.39 and the highest is $1.47. Steris reported earnings per share of $1.26 in the same quarter last year, which indicates a positive year over year growth rate of 13.5%. The company is expected to announce its next earnings results on Monday, February 10th.
According to Zacks, analysts expect that Steris will report full-year earnings of $5.57 per share for the current financial year, with EPS estimates ranging from $5.48 to $5.61. For the next fiscal year, analysts expect that the business will post earnings of $6.10 per share, with EPS estimates ranging from $5.93 to $6.20. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Steris.
Steris (NYSE:STE) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.32 EPS for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.06. Steris had a net margin of 11.59% and a return on equity of 16.15%. The firm had revenue of $736.84 million during the quarter, compared to analysts’ expectations of $717.79 million. During the same period in the previous year, the business posted $1.10 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year.
Separately, ValuEngine cut shares of Steris from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $148.20.
STE stock traded up $2.01 during midday trading on Friday, reaching $148.75. 287,183 shares of the company were exchanged, compared to its average volume of 446,387. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.41 and a quick ratio of 1.86. The business has a 50-day moving average price of $142.07 and a two-hundred day moving average price of $143.71. Steris has a one year low of $99.14 and a one year high of $156.66. The firm has a market capitalization of $12.35 billion, a price-to-earnings ratio of 30.42 and a beta of 0.88.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 20th. Stockholders of record on Tuesday, November 26th will be given a $0.37 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 0.99%. Steris’s payout ratio is presently 30.27%.
In other news, VP John Adam Zangerle sold 1,000 shares of the business’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $142.15, for a total value of $142,150.00. Insiders own 2.36% of the company’s stock.
Several institutional investors have recently made changes to their positions in STE. Squar Milner Financial Services LLC boosted its position in shares of Steris by 225.9% in the third quarter. Squar Milner Financial Services LLC now owns 176 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 122 shares during the period. Ropes Wealth Advisors LLC acquired a new position in Steris in the second quarter valued at about $26,000. Quest Capital Management Inc. ADV acquired a new position in Steris in the third quarter valued at about $26,000. Evolution Wealth Advisors LLC acquired a new position in Steris in the second quarter valued at about $27,000. Finally, Krane Funds Advisors LLC acquired a new position in Steris in the second quarter valued at about $27,000. 87.58% of the stock is owned by institutional investors.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
See Also: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.